Adverse events as a potential clinical marker of antitumor efficacy in ovarian cancer patients treated with poly ADP-ribose polymerase (PARP) inhibitor-MedSci.cn

Adverse events as a potential clinical marker of antitumor efficacy in ovarian cancer patients treated with poly ADP-ribose polymerase (PARP) inhibitor

Ni, J; Chen, XX; Xu, X; Guo, WW; Cheng, XZ; Zhao, Q; Gu, HY; Zhou, R; Chen, C

GYNECOLOGIC ONCOLOGY, 2021; 162 (): S85

科室
- - 订阅+
  - 更多科室
工具
服务